Differentiated thyroid cancer (DTC) is the most common type of thyroid cancer. Of those patients diagnosed with DTC, approximately 5 to 15% may be RAI-Refractory. There is currently no consensus that defines RAI-refractory differentiated thyroid cancer (RAIR-DTC) or offers clinical scenarios that are an absolute indicator of the condition. To address this topic, this program consists of short educational videos on Differentiated thyroid cancer and the treatment of RAI-Refractory patients. Dr. Stan VanUum and Dr. Dean Ruether will discuss common issues healthcare professionals, including endocrinologists and oncologists, may have concerning the challenges of identifying and treating RAIR-DTC patients.
Closing the Knowledge Gap: RAI-Refractory Differentiated Thyroid Cancer
CAN-eng
$0
free
MOC - Section 3
30 mins
Endocrinology, Oncology
0.5 Credits
Course Description
Course Details
Expiry Date: 2021-02-14
Professions: Physician, Specialist
Faculty
Dr. Andree Boucher, MD, FRCPC
Dr. Murali Rajamaran, MD, FRCPC
Dr. Stan VanUum, MD, PhD, FRCPC
Dr. Dean Ruether, MD, FRCPC
Accreditation
This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians & Surgeons of Canada, and approved by the Canadian Society of Endocrinology and Metabolism. Remember to visit MAINPORT to record your learning and outcomes. You may claim a maximum of 0.5 hours (credits are automatically calculated).
Accreditation ID: 00011681.
Learning Objective(s)
Upon completion of this program, the participants will be able to:
- Identify differentiated thyroid cancer patients likely to be RAI-Refractory (RAIR-DTC)
- Initiate treatment with a tyrosine kinase inhibitor (TKI) in RAI-Refractory Differentiated Thyroid Cancer (RAIR-DTC) patients
- Manage adverse events associated with TKIs, including prevention and early detection
- Address the challenges of patient expectations